Journal of Antimicrobial Chemotherapy (1999) 44, 477-481
© 1999 The British Society for Antimicrobial Chemotherapy
Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniaein a murine sepsis model
a Department of Pharmacy Practice, School of Pharmacy, The University of Kansas Medical Center, Kansas City, KS 66160-7231 b Department of Pharmacy Research, Hartford Hospital, Hartford, CT 06102-5037, USA c Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102-5037, USA d Office of Research Administration, Hartford Hospital, Hartford, CT 06102-5037, USA
Trovafloxacin is a new fluoroquinolone that has potent microbiological activity against the pneumococcus, including penicillin-resistant strains. To evaluate the protective effect of trovafloxacin, ciprofloxacin and ampicillin against penicillin-susceptible, -intermediate and -resistant strains of Streptococcus pneumoniae, an intraperitoneal, immunocompetent mouse model of sepsis was used. The minimum lethal dose (MLD) for each isolate was determined in duplicate. A single sc dose of each antibiotic was administered over a wide range of doses 1 h after the ip inoculation of the test isolate at the MLD. The assessment of the protective dose for 50% of the population (PD50) for each antimicrobial/bacteria combination was performed in triplicate and the PD50 value was calculated at the end of 5 days. Results showed that trovafloxacin provided PD50 values that were significantly lower than those of ciprofloxacin for all isolates. For the penicillin-susceptible and -intermediate isolates, the PD50 values of ampicillin were significantly lower than those for either of the fluoroquinolones studied; however, trovafloxacin was statistically superior to both ciprofloxacin and ampicillin against the penicillin-resistant strain. Therefore, regardless of penicillin susceptibility, trovafloxacin has potent activity against Streptococcus pneumoniae and may be a viable alternative for the treatment of penicillin-resistant isolates.
* Correspondence address. Hartford Hospital, Division of Infectious Diseases, 80 Seymour Street, PO Box 5037, Hartford, CT 06102-5037, USA. Tel: +1-860-545-3941; Fax: +1-860-545-5112; E-mail: dnicola{at}harthosp.org
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Chiavolini, G. Pozzi, and S. Ricci Animal Models of Streptococcus pneumoniae Disease Clin. Microbiol. Rev., October 1, 2008; 21(4): 666 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, T. N. C. Ramya, A. Surolia, and N. Surolia Triclosan as a Systemic Antibacterial Agent in a Mouse Model of Acute Bacterial Challenge Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3859 - 3866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Cubbon and R. G. Masterton New quinolones--a fresh answer to the pneumococcus J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872. [Full Text] [PDF]
|
|